Remsima 100 mg powder for concentrate for solution for infusion

*
Pharmacy Only: Prescription
  • Company:

    Celltrion Healthcare Ireland Ltd.
  • Status:

    Updated
  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)
  • Active Ingredient(s):

    *Additional information is available within the SPC or upon request to the company

qrcode image

Scan the QR code or enter an email to access and share this medicine:

Updated on 26 May 2025

File name

PIL_Remsima 100 mg IV vial_en_May 2025.pdf

Reasons for updating

  • Change to section 4 - possible side effects

Free text change information supplied by the pharmaceutical company

EU Product Information (PI) update for alignment with reference product.

Not known:

(…)

  • Infection due to a live vaccine because of a weakened immune system.
  • Problems following a medical procedure (including infectious and non-infectious problems).


Updated on 26 May 2025

File name

SmPC_Remsima 100 mg IV vial_en_v46.0_May 2025.pdf

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

EU Product Information (PI) update for alignment with reference product updates.

SmPC Section 4.4 - Others

There is limited safety experience of infliximab treatment in patients who have undergone surgical procedures, including arthroplasty. The long half life of infliximab should be taken into consideration if a surgical procedure is planned. A patient who requires surgery while on infliximab should be closely monitored for infectiousns and non-infectious complications, and appropriate actions should be taken (see section 4.8).

Updated on 09 August 2024

File name

SmPC_Remsima 100 mg IV vial_en_Aug 2024.pdf

Reasons for updating

  • New SPC for medicines.ie

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 18 June 2024

File name

remsima-epar-product-information_en.pdf

Reasons for updating

  • New SPC for new product

Legal category:Product subject to medical prescription which may not be renewed (A)

EDM Updated on 17 June 2024

File name

CT-P13 100mg_PAC(IE)_final(Egis)_30Aug22.pdf

Reasons for updating

  • Add New Doc

Updated on 17 June 2024

File name

CT-P13 100mg_Leaflet(IE)_final(400x492)(Egis)_16Jan23.pdf

Reasons for updating

  • New PIL for new product

Celltrion Healthcare Ireland Ltd.

Celltrion Healthcare Ireland Ltd.